|
Eliot M. Lurier joined Interleukin Genetics Inc. as CFO in April 2008. Mr. Lurier has more than 25 years of financial and operational management experience primarily in the life sciences industry. Prior to joining Interleukin Genetics he was Vice President Finance and Administration and Chief Financial Officer of NUCRYST Pharmaceuticals where he successfully completed a $45 million IPO within 6 months of joining the company and was responsible for SEC reporting and the implementation of Sarbanes-Oxley requirements. Previously he served as Chief Financial Officer and Chief Operating Officer for Bridge Pharmaceuticals Inc. where he established all policies for managing business operations. Prior to joining Bridge Pharmaceuticals Inc. Mr. Lurier held a number of senior-level financial positions including Chief Financial Officer of Admetric Biochem Inc. and Chief Financial Officer Treasurer and Vice President of Finance of Ascent Pediatrics Inc. a publicly traded pharmaceutical company. Earlier in his career Mr. Lurier was a Senior Accountant at Coopers and Lybrand. He earned a B.S. in Accounting from Syracuse University and is a Certified Public Accountant in Massachusetts. | 